Did you mean: Paula Stubbeman
Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort …
…, G Schwanitz, AS Sinnigen, P Stubbemann… - The Lancet …, 2021 - thelancet.com
Background Heterologous vaccine regimens have been widely discussed as a way to
mitigate intermittent supply shortages and to improve immunogenicity and safety of COVID-19 …
mitigate intermittent supply shortages and to improve immunogenicity and safety of COVID-19 …
[PDF][PDF] Early IFN-α signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19
…, BM Kümmerer, V Keitel, B Jensen, P Stubbemann… - Immunity, 2021 - cell.com
Longitudinal analyses of the innate immune system, including the earliest time points, are
essential to understand the immunopathogenesis and clinical course of coronavirus disease (…
essential to understand the immunopathogenesis and clinical course of coronavirus disease (…
[PDF][PDF] A time-resolved proteomic and prognostic map of COVID-19
…, C Correia-Melo, SK Aulakh, ET Helbig, P Stubbemann… - Cell systems, 2021 - cell.com
COVID-19 is highly variable in its clinical presentation, ranging from asymptomatic infection
to severe organ damage and death. We characterized the time-dependent progression of …
to severe organ damage and death. We characterized the time-dependent progression of …
[HTML][HTML] Increased risk of severe clinical course of COVID-19 in carriers of HLA-C* 04: 01
…, A Jaitovich, ET Helbig, LJ Lippert, P Stubbemann… - …, 2021 - thelancet.com
Background Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic,
there has been increasing urgency to identify pathophysiological characteristics leading to …
there has been increasing urgency to identify pathophysiological characteristics leading to …
[HTML][HTML] CD4+ T cell calibration of antigen-presenting cells optimizes antiviral CD8+ T cell immunity
…, L Petrov, S Brumhard, P Stubbemann… - Nature …, 2023 - nature.com
Antiviral CD8 + T cell immunity depends on the integration of various contextual cues, but how
antigen-presenting cells (APCs) consolidate these signals for decoding by T cells remains …
antigen-presenting cells (APCs) consolidate these signals for decoding by T cells remains …
[HTML][HTML] A proteomic survival predictor for COVID-19 patients in intensive care
…, LJ Lippert, ET Helbig, P Stubbemann… - PLOS Digital …, 2022 - journals.plos.org
Global healthcare systems are challenged by the COVID-19 pandemic. There is a need to
optimize allocation of treatment and resources in intensive care, as clinically established risk …
optimize allocation of treatment and resources in intensive care, as clinically established risk …
[HTML][HTML] The brain reacting to COVID-19: analysis of the cerebrospinal fluid proteome, RNA and inflammation
…, M Venø, B Teegen, W Stöcker, P Stubbemann… - Journal of …, 2023 - Springer
Patients with COVID-19 can have a variety of neurological symptoms, but the active
involvement of central nervous system (CNS) in COVID-19 remains unclear. While routine …
involvement of central nervous system (CNS) in COVID-19 remains unclear. While routine …
[HTML][HTML] Clinical and virological characteristics of hospitalised COVID-19 patients in a German tertiary care centre during the first wave of the SARS-CoV-2 pandemic …
…, LA Meyer-Arndt, L Meiners, P Stubbemann… - Infection, 2021 - Springer
Purpose Adequate patient allocation is pivotal for optimal resource management in strained
healthcare systems, and requires detailed knowledge of clinical and virological disease …
healthcare systems, and requires detailed knowledge of clinical and virological disease …
[HTML][HTML] Early and rapid identification of COVID-19 patients with neutralizing type I interferon auto-antibodies
B Akbil, T Meyer, P Stubbemann, C Thibeault… - Journal of clinical …, 2022 - Springer
Purpose Six to 19% of critically ill COVID-19 patients display circulating auto-antibodies against
type I interferons (IFN-AABs). Here, we establish a clinically applicable strategy for early …
type I interferons (IFN-AABs). Here, we establish a clinically applicable strategy for early …
[HTML][HTML] Short-and long-term T cell and antibody responses following dexamethasone treatment in COVID-19
…, V di Cristanziano, KA Eberhardt, P Stubbemann… - JCI insight, 2023 - ncbi.nlm.nih.gov
BACKGROUND After its introduction as standard-of-care for severe COVID-19, dexamethasone
has been administered to a large number of patients globally. Detailed knowledge of its …
has been administered to a large number of patients globally. Detailed knowledge of its …
Did you mean to search for: Paula Stubbeman